The Different Approaches to Leukemia Management

The approach to this generally has evolved with the introduction of Venetoch lags. It used to be hypometallating agents only, as a citadine or a dysitubine. But that gave you a median overall survival of close to nine to ten months. So your goal here becomes more palliative. You are trying to extend the survival, keep the patient out of the hospital as much as possible.